Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00162968
Status:
COMPLETED
Last Update Posted:
2007-04-24
First Post:
2005-09-09
Brief Title:
Escitalopram as a Treatment for Pain in Polyneuropathy
Sponsor:
Odense University Hospital
Organization:
Odense University Hospital
Study Overview
Official Title:
Escitalopram as a Treatment for Pain in Polyneuropathy A Double-Blind Randomized Placebo Controlled Trial
Status:
COMPLETED
Status Verified Date:
2007-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Many people with polyneuropathy suffer from pain which is difficult to treat Escitalopram is a relatively new drug used in the treatment of depression Escitaloprams action mechanism on the brain suggests that escitalopram also may have an effect on neuropathic pain This study will test the efficacy of escitalopram in patients with painful polyneuropathy
Detailed Description:
Tricyclic antidepressants appear to be the most efficacious treatment of painful polyneuropathy However these drugs are contraindicated in some patients and a substantial number of patients decline treatment due to side-effects Therefore effective drugs that are better tolerated are needed Clinical and basic research has demonstrated that drugs with serotonergic action can alleviate neuropathic pain Escitalopram increases serotonin concentration in the central nervous system suggesting that it might be a potential alternative to current treatments of neuropathic pain The aim of this study is to test if escitalopram would relieve painful polyneuropathy
Comparisons Treatment with 20 mg escitalopram daily will be compared in a cross-over design with placebo Each treatment period will last 6 weeks During the last week of each treatment period the dose will be tapered
Comparisons Treatment with 20 mg escitalopram daily will be compared in a cross-over design with placebo Each treatment period will last 6 weeks During the last week of each treatment period the dose will be tapered
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None